Plain language summary examining clinical event related costs associated with changing medication from apixaban to rivaroxaban in people with non-valvular atrial fibrillation in the USA and Germany [0.03%]
简易概述：从阿哌沙班换用利伐沙班对美国和德国非瓣膜性房颤患者相关临床事件费用的影响分析
Rupesh Subash,Cecilia Duan,Dionne M Hines et al.
Rupesh Subash et al.
Economic burden of advanced non-small cell lung cancer (NSCLC): a systematic literature review [0.03%]
晚期非小细胞肺癌(NSCLC)的经济负担：系统文献回顾
Nick Jovanoski,Gavneet Kaur,Hemlata Shukla et al.
Nick Jovanoski et al.
Aims: A systematic review of the economic burden of advanced non-small-cell lung cancer (NSCLC). Methods: Articles from 2011 onwards re...
The healthcare resource utilization and costs associated with metabolic dysfunction-associated steatohepatitis among Medicare beneficiaries: a retrospective cohort study [0.03%]
一项针对Medicare受益人与代谢功能障碍相关肝炎资源利用和成本的回顾性队列研究
Husam Albarmawi,Anran Tan,Abdalla Aly et al.
Husam Albarmawi et al.
Aims: The main objective of this study was to estimate the incremental healthcare resource utilization (HCRU) and costs attributable to metabolic dysfunction-associated steatohepatitis (MASH) from a Medicare fee-for-servi...
Observational Study
Journal of medical economics. 2026 Dec;29(1):498-515. DOI:10.1080/13696998.2026.2630601 2026
Clinical and economic benefits of combined genetic and genomic testing strategies to guide treatment decisions for patients with HR+/HER2- breast cancer in the US [0.03%]
在美国，联合基因组学和遗传学检测策略指导HR+/HER2-乳腺癌患者治疗决策的临床和经济效益分析
M Gouldson,Q Le,S Millen et al.
M Gouldson et al.
Background: In the US, breast cancer is the most common female cancer. Personalized treatment strategies, informed by genomic assays and germline genetic testing (GGT), can optimize therapeutic decisions and improve patie...
Correction [0.03%]
改正通知书
Published Erratum
Journal of medical economics. 2026 Dec;29(1):431-432. DOI:10.1080/13696998.2026.2632462 2026
Health state utilities for relapsed or refractory large B-cell lymphoma treatments: a time trade-off study in the Japanese general population [0.03%]
日本普通人群复发或难治性大B细胞淋巴瘤治疗的健康状态效用权重：时间交易法研究
Shigeo Fuji,Hiroshi Ando,Kana Takaura et al.
Shigeo Fuji et al.
Aim: Conventional therapies in Japan for relapsed or refractory large B-cell lymphoma (r/r LBCL) require intravenous infusion (IV), while epcoritamab is administered subcutaneously. Despite the expected quality of life (Q...
Time to access matters: patient gains from faster CAR T-cell reimbursement in Europe [0.03%]
时效就是疗效 — 欧洲更快的CAR-T细胞报销带来的患者获益
Yan Zhi Tan,Emily Breislin,Matthew Woods et al.
Yan Zhi Tan et al.
Background: Despite clinical efficacy and cost-effectiveness, time to reimbursement for chimeric antigen receptor (CAR) T-cell therapies varies greatly across Europe. We examined these differences, and quantified potentia...
Delta price cost-effectiveness analysis of PCV21 vs PCV20 use in adults aged ≥65 years in Switzerland [0.03%]
瑞士≥65岁老年人群中PCV21与PCV20的增量成本效益分析
Muloongo Simuzingili,Andrea Favre-Bulle,Thomas Mutschler et al.
Muloongo Simuzingili et al.
Introduction: This study evaluated the health and economic impacts of the 21-valent pneumococcal conjugate vaccine (PCV21) compared to the 20-valent pneumococcal conjugate vaccine (PCV20) in Swiss adults aged 65 years and...
Health and productivity benefits of anti-PD-(L)1 agents for early-stage cancer treatment in Hungary [0.03%]
抗PD-(L)1药物治疗匈牙利早期癌症患者的健康和生产力收益
Daniel Ladino,Karl Patterson,Máté Várnai et al.
Daniel Ladino et al.
Aim: Anti-PD-(L)1 agents, inhibitors of programmed cell death protein 1 (PD-1) or its ligand (PD-L1), are established therapies that improve cancer management as well as the disease and societal burden of specific metasta...
The economic value of self-administered subcutaneous immunoglobulin G (SCIg) in Canada: a scoping review [0.03%]
加拿大自体皮下免疫球蛋白(SCIg)的经济价值：一项系统综述
Antoinette Cheung,Megan Manuel,Stephen Mac et al.
Antoinette Cheung et al.
Background: Subcutaneous immunoglobulin (SCIg) is a treatment available in Canada for patients requiring antibody replacement. While standard-of-care involves in-hospital intravenous Ig (IVIg) treatment, SCIg allows for h...